Veterinary Anti-Infective Market

Veterinary Anti-Infective Market Study by Antimicrobial Agents, Antiviral Agents, Antifungal Agents, and Antiparasitic Agents for Livestock and Companion Animals from 2024 to 2034

Analysis of Veterinary Anti-Infective Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Veterinary Anti-Infective Market Outlook (2024 to 2034)

Revenue from the global veterinary anti-infective market size is estimated to reach US$ 5.03 billion in 2024. The market is analyzed to climb to a value of US$ 7.47 billion by the end of 2034, expanding at a CAGR of 4%.

Anti-infectives are products that help prevent the spread or transmission of diseases. Moreover, veterinary anti-infectives are instrumental in halting or treating the transmission of infectious diseases between humans and animals.

Use of anti-infectives has increased in recent years due to the rising demand for animal products such as meat, milk, and other foods, as well as diseases associated with these animals. The natural transmission of zoonotic and foodborne illnesses from animals to humans occurs when a human comes into contact with an infected animal or person, consumes contaminated food or water, or is exposed to the pathogen during preparation or processing.

An antimicrobial drug's ability to inhibit or kill bacteria is determined by its mechanism of action and the concentration at the infection site. A drug's antibacterial activity is chemically altered or decreased, and its excretion is aided, by the liver, kidneys, and other organs that quickly absorb it through the bloodstream.

Key Market Growth Drivers

  • Focus on the prevention and treatment of fatal animal diseases are important driving demand for veterinary antibiotics. Several factors, including the surge in foodborne and zoonotic diseases, the increasing popularity of pets, and the expansion of research and development in animal healthcare, contribute to the expanding size of the veterinary anti-infective market.
  • The rising trend of pet ownership is projected to contribute to the expansion of the veterinary anti-infective market size. More and more individuals, particularly young people, are embracing pets as integral members of their families. Some adopt pets to alleviate loneliness and benefit from their companionship and loyalty.
  • Increasing livestock production is a key driver for market growth. These medications play a crucial role in treating animal infections and promoting their overall health and well-being. They are indispensable for both preventing and managing illnesses within the animal population.
  • Escalation of foodborne illnesses stands out as a primary catalyst for the expansion of the anti-infective drug market. Animals serve as significant sources of infectious diseases that can be transmitted to humans. Controlling these diseases is paramount for public health officials due to the threats they pose to human well-being.
  • The growing trend of pet adoption, coupled with mounting concerns about pet health and the prevalence of bacterial infections, particularly among dogs, is poised to drive veterinary anti-infective market growth.
Report Attribute Detail
Veterinary Anti-Infective Market Size (2024E) US$ 5.03 Billion
Forecasted Market Value (2034F) US$ 7.47 Billion
Global Market Growth Rate (2024 to 2034) 4% CAGR
Latin America Market Share (2024E) 13%
North America Market Share (2024E) 34.4%
Revenue from Veterinary Clinics (2024E) US$ 1.9 Billion
Key Companies Profiled Neogen Corporation; Phibro Animal Health Corporation; Sanofi (Merial Animal Health); Vetoquinol S.A.; Virbac S.A.; Zoetis, Inc.; Boehringer Ingelheim GmbH; Ceva Santé Animale; Indian Immunologicals Limited; Intas Pharmaceuticals Limited; Norbrook Laboratories Limited; Ashish Life Science Private; Zydus Animal Health Limited.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Why is There Steadily Growing Demand for Veterinary Care and Anti-Infectives?

“Increasing Pet Humanization Driving Focus on Their Healthcare and Well-Being”

Global surge in pet adoption, notably of dogs and cats, is contributing to concerns regarding the health and hygiene of these animals, thereby driving sales of anti-infectives. Growing demand for pet companionship and the corresponding need for veterinary care are key veterinary anti-infective market trends. Dogs and cats, in particular, are susceptible to bacterial diseases like the plague, among others.

Animals can potentially transmit diseases to humans, underscoring the importance of increased pet vaccination rates to control and treat these ailments. Ongoing research aims to develop novel and more efficacious medications, with human trials underway to assess their effectiveness.

What Challenges are Manufacturers of Veterinary Anti-Infectives Facing?

“Rising Antimicrobial Resistance and Availability of Generic Alternatives”

Veterinary anti-infective manufacturers are encountering significant challenges due to rising antimicrobial resistance. To address concerns about antimicrobial resistance (AMR), regulatory authorities are increasingly focused on ensuring the responsible use of antibiotics and other anti-infective agents in animals. The presence of generic alternatives to branded veterinary anti-infectives presents a competitive hurdle for market participants, as cost-conscious consumers opt for cheaper options. Maintaining market share requires differentiation through superior product quality and efficacy.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Country-wise Insights

North America is expected to occupy a revenue share of 34.4% in 2024. The growth of this regional market is projected to be fueled by the existence of cutting-edge animal healthcare programs and increased public awareness of animal health during the forecast period.

  • To address the issues affecting the animal health industry, the North American Pet Health Insurance Association is focusing on raising awareness of pet health insurance coverage and creating and investigating partnerships.

Need for quick and efficient treatment options is also being driven by the increased prevalence of diseases in pets and livestock, which is expected to fuel demand for veterinary anti-infectives in the region.

  • The Food and Agriculture Organization (FAO) estimates that there are more than 1.4 billion cattle worldwide, with a sizable portion of them living in nations like China, Brazil, and India.

What’s Driving Veterinary Anti-Infective Sales in the United States?

“Extensive Use of Veterinary Anti-Infectives to Preserve Safety of Animal Products”

Attribute United States
Market Value (2024E) US$ 1.17 Billion
Growth Rate (2024 to 2034) 3.5% CAGR
Projected Value (2034F) US$ 1.65 Billion

The United States is set to hold 67.8% of the veterinary anti-infective market share in North America in 2024. Growing demand for anti-infectives for companion animals is driven by the rising number of pet owners in the United States. Veterinarian prescriptions for both preventive and therapeutic purposes are being used more frequently as a result of growing pet owners' concerns about their animals' health.

Due to the high demand for premium meat in the United States, livestock are effectively prevented from contracting diseases and treated when they do. Ensuring the health of farm animals becomes increasingly important as consumers are becoming more health-conscious. Veterinary anti-infectives are essential to preserving food safety and animal health.

How is the Market for Veterinary Anti-Infectives Evolving in Brazil?

“Large Cattle Population Prompting Increased Control Over Veterinary Anti-infectives”

Attribute Brazil
Market Value (2024E) US$ 319 Million
Growth Rate (2024 to 2034) 4.5% CAGR
Projected Value (2034F) US$ 496 Million

Brazil is a lucrative market for producers of anti-infectives due to its large cattle population. Brazil has been enforcing stricter regulations on the use of antibiotics and other anti-infectives in veterinary medicine. Concerns regarding antimicrobial resistance and its effects on the health of humans and animals have prompted some of these measures.

Consequently, there is more oversight and control over veterinary anti-infectives, such as limitations on specific antibiotic classes or the need for prescriptions to use them. Knowledge of the significance of appropriate antibiotic use and the effects of antimicrobial resistance is expanding among veterinarians, pet owners, and livestock producers. As a result, there is now more focus on preventive measures that reduce the need for anti-infective medications, such as vaccination, biosecurity, and good hygiene practices.

Category-wise Insights

The global market is divided into two main segments: antiviral agents and antimicrobial agents. In terms of species, it is classified into livestock animals, and companion animals, of which the former is set to hold a market share of 67.6% in 2024. Anti-infectives are administered through oral, parenteral, and topical modes of administration and are distributed through veterinary hospitals, veterinary clinics, pharmacies, and other channels.

Why Do Antimicrobial Agents Account for a Significant Market Share?

“Wide Usage of Antimicrobial Agents Driven by Their Proven Efficacy”

Attribute Antimicrobial Agents
Segment Value (2024E) US$ 2.73 Billion
Growth Rate (2024 to 2034) 3.9% CAGR
Projected Value (2034F) US$ 4.01 Billion

In the drug class segment, the antimicrobial agents sub-segment is projected to account for a 50% market share during the forecast period. Antimicrobial agents that find widespread usage include tetracyclines, cephalosporins, and Penicillin. In terms of revenue, the antimicrobial agents segment is leading the global veterinary anti-infective market, and this pattern is forecasted to hold steady throughout the forecast period.

How are Veterinary Hospitals and Clinics Contributing to Market Growth?

“Hospitals and Clinics Ensuring Compliance with Regulations for Veterinary Anti-infective Use”

Attribute Veterinary Clinics
Segment Value (2024E) US$ 1.9 Billion
Growth Rate (2024 to 2034) 4.1% CAGR
Projected Value (2034F) US$ 2.85 Billion

Veterinary clinics and hospitals are poised to account for 70% market share in 2024. Stricter regulations being put in place to prevent animal diseases and growing awareness of veterinary healthcare are driving demand for veterinary anti-infectives in hospitals and clinics. Over the course of the forecast period, an increasing number of government initiatives to promote veterinary services in hospitals and clinics are projected to fuel market growth.

Guidelines for veterinary health are being released by government organizations, which is fueling market expansion.

  • As an illustration, the WTO framework's OIE International Standards published guidelines to enhance veterinary care and advance global animal health.

By rejecting goods that do not meet set standards, these actions can help with the early detection, control, and reporting of pathogenic agents and stop their spread.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Competitive Landscape

Key players in the veterinary anti-infective market have enormous opportunities to invest in the global veterinary anti-infective market through biologics and specialty care. Focus on research aimed at improving the efficacy of veterinary anti-infectives is driving market growth.

  • The Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched in November 2022 by the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO), and the World Organization for Animal Health (WOAH), also known as the Quadripartite. In addition to ensuring that the effects of antimicrobial resistance are addressed globally, this project aims to draw attention to the threat that antimicrobial resistance (AMR) poses to people, animals, plants, ecosystems, and livelihoods.
  • The United States-based pharmaceutical company Elanco Animal Health Incorporated, which produces medications and vaccines for pets and livestock, introduced Increxxa, the recently approved medication for livestock respiratory disease, in February 2021.
    • Tulathromycin, the main ingredient in Increxxa, is injected into cattle to target the infection site in the lungs quickly. This fast action and long half-life give the cattle more time to build up a robust defense. The active component of Increxxa, tulathromycin, helps lessen the harmful effects of bovine respiratory disease; this product is intended for veterinary use.

Fact.MR provides detailed information about the price points of key providers of veterinary anti-infectives positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.

Segmentation of Veterinary Anti-Infective Market Research

  • By Species :

    • Livestock Animals
    • Companion Animals
  • By Drug Class :

    • Antimicrobial Agents
    • Antiviral Agents
    • Antifungal Agents
    • Antiparasitic Agents
  • By Mode of Administration :

    • Oral
    • Parenteral
    • Topical
  • By Distribution Channel :

    • Veterinary Hospitals
    • Veterinary Clinics
    • Pharmacies
  • By Region :

    • North America
    • Western Europe
    • Eastern Europe
    • Latin America
    • East Asia
    • South Asia & Pacific
    • Middle East & Africa

- FAQs -

How big is the veterinary anti-infective market?

The global market for veterinary anti-infectives is estimated at US$ 5.03 billion in 2024.

What are the sales projections for veterinary anti-infectives over the decade?

The global market is forecasted to expand at 4% CAGR and reach US$ 7.47 billion by the end of 2034.

Which country has a significant market for veterinary anti-infectives?

Revenue from veterinary anti-infectives in the United States is projected to reach US$ 1.17 billion in 2024.

What are the projections for the market in Brazil?

Brazil is estimated to reach a market value of US$ 319 million in 2024.

Which distribution channel accounts for higher sales of veterinary anti-infectives?

Revenue from veterinary anti-infective clinics is expected to reach US$ 1.9 billion in 2024.

What is the share of Canada in the North American market?

Canada accounts for a market share of 21.2% in North America in 2024.

Who are the leaders in the business of veterinary anti-infectives?

Ceva Santé Animale, Indian Immunologicals Limited, Intas Pharmaceuticals Limited, Norbrook Laboratories Limited, and Ashish Life Science Private are key market players.

- Also of Interest -

Veterinary Endoscopy Market

Veterinary Endoscopy Market Size, Share, Forecast & Growth Analysis By Product (Flexible, Videoscope, Fibreoptic, Rigid), By Animal Type (Companion Animals, Large Animals), By End User (Hospitals, Academic Institutes, Clinics), & By Region - Global Market Insights 2022-2027

Veterinary Artificial Insemination Market

Veterinary Artificial Insemination Market Analysis by Animal Type (Cattle, Swine, Ovine, Equine Veterinary Artificial Insemination), by Product (Normal Semen, Sexed Semen), by End User & Region - Global Forecast 2022-2032

Veterinary Oncology Market

Veterinary Oncology Market Analysis by Radiology, Chemotherapy, Combination Therapy, Immunotherapy, and Targeted Therapy from 2023 to 2033

Veterinary Hematology Analyzers Market

Veterinary Hematology Analyzers Market Analysis By Product (Table Top Analyzers, Point-of-Care Analyzers), By Analysis Parameter (2-Part WBC Differential, 3-Part WBC Differential, 5-Part WBC Differential), By End User & Region - Global Market Insights 2023-2033

Veterinary Anti-Infective Market